

Memorial Sloan Kettering Cancer Center presents:

2nd International Symposium on **Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy**

OCTOBER 11-12, 2019

ZUCKERMAN RESEARCH CENTER
NEW YORK, NY



**Memorial Sloan Kettering
Cancer Center**



LINEBERGER COMPREHENSIVE
CANCER CENTER



American Society for
Transplantation and Cellular Therapy

OVERVIEW

Today, more than 10,000 hematopoietic cell transplantations (HCTs) are performed yearly in the United States as treatment for more than 70 life threatening illnesses including cancers, genetic disorders, and other diseases. Also, given the shift toward cellular therapies in the field of HCT, the number of patients treated with these novel biologic agents is rapidly increasing.

Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.

The target audience for this symposium includes physicians, researchers, fellows, advanced practice providers, nurses, pharmacists, data managers, and other healthcare professionals who provide care for patients undergoing HCT and cellular therapies.

Educational Objectives

- Understand the mechanisms of the most common treatment-related toxicities after HCT and cellular therapy.
- Identify best practices to prevent and treat toxicities and symptom burden after HCT and cellular therapy to improve the patient experience and reduce non-relapse mortality.
- Understand how to approach prevention and treatment of toxicities and symptom burden in unique HCT and cellular therapy patient populations.

Call for Abstracts

Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Abstract submission is open to all, and we also highly encourage fellows, residents, pharmacists, and advanced practice providers to submit relevant abstracts in the area of biology, prevention, and treatment of toxicities after transplantation and cellular therapy. In addition, abstracts related to trials and/or clinical research in progress will be accepted. Top awarded abstracts will receive a travel grant tied to attending this symposium.

Submission Deadline: September 14, 2019

Live Simulcast Available

Visit mskcc.org/toxicities for more information or to register.

This symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms.


Course Directors



Sergio A. Giralt, MD
Memorial Sloan Kettering Cancer Center



Michael Scordo, MD
Memorial Sloan Kettering Cancer Center



William A. Wood, MD
UNC Lineberger Comprehensive Cancer Center

Organizing Committee



Miguel Perales, MD
Memorial Sloan Kettering Cancer Center



Maria Cancio, MD
Memorial Sloan Kettering Cancer Center



David Faleck, MD
Memorial Sloan Kettering Cancer Center



Gabriela Rondon, MD
MD Anderson Cancer Center



Navneet S. Majhail, MBBS, MD, MS
Cleveland Clinic



Bipin N. Savani, MD
Vanderbilt-Ingram Cancer Center



Shernan Holtan, MD
University of Minnesota



Kenneth R. Cooke, MD
Johns Hopkins
Sidney Kimmel Cancer Center



Minoo Battiwalla, MD, MS
Sarah Cannon Center
for Blood Cancer

FACULTY

Invited Course Faculty

Keynote Speaker



Andrea Bacigalupo, MD
Policlinico A. Gemelli
Rome, Italy

Department of Medicine Grand Rounds Lecturer



George McDonald, MD
Fred Hutchinson Cancer
Research Center

Rajni Agarwal-Hashmi, MD
Stanford

Andrew Artz, MD, MS
City of Hope

Ami Bhatt, MD, PhD
Stanford

Sita Bhella, MEd, MD
University of Toronto

Kira Bona, MD, MPH
Dana Farber/Boston Children's

Chris Bredeson, MD, MSc, FRCPC
Ottawa Hospital Research Institute
Ottawa, ON, Canada

Mitchell Cairo, MD
New York Medical College

Louis Cohen, MD
Mt Sinai

Christopher Dandoy, MD, MS
Cincinnati Children's Hospital Medical Center

Christine Duncan, MD
Dana Farber/Boston Children's

Areej R. El-Jawahri, MD
Massachusetts General Hospital

Mareike Frick, MD
Charite UMC
Berlin, Germany

Theresa Hahn, PhD
Roswell Park Comprehensive Cancer Center

MSK Course Faculty



JJ Boelens, MD, PhD



Christian Otto, MD, MMSc, DABFM

Keynote Speaker



Bronwen E Shaw, MD, PhD
Medical College of Wisconsin

Melissa Hudson, MD
St. Jude Children's Research Hospital

Richard J. Jones, MD
Johns Hopkins

Benjamin Laskin, MD, MS
Children's Hospital of Philadelphia

Hillard Lazarus, MD, FACP
University Hospitals Cleveland Medical Center

John K. Lin, MD
Perelman School of Medicine at the
University of Pennsylvania

Caroline Lindemans, MD, PhD
UMC Utrecht
Utrecht, Netherlands

Thomas Luft, MD, PhD
Heidelberg University Hospital
Heidelberg, Germany

Kerry McMillen, MS, RD, CSO, FAND
Fred Hutchinson Cancer Research Center

Pawel Muranski, MD
Columbia University Medical Center

Stefan Nierkens, PhD
UMC Utrecht
Utrecht, Netherlands

Pavan Reddy, MD
University of Michigan
Comprehensive Cancer Center

Karen Syrjala, PhD
Fred Hutchinson Cancer Research Center



Jessica Scott, PhD

SCHEDULE

DAY 1 • FRIDAY, OCTOBER 11

7:00 AM Registration and Breakfast

7:50 AM **Welcome, Opening Remarks and Conference Overview**
Sergio A. Giral, MD
Michael Scordo, MD

Gastrointestinal Toxicity, Nutrition and the Microbiome

MODERATORS: David Faleck, MD and Kenneth R. Cooke, MD

8:00 AM **Department of Medicine Grand Rounds**
GI and Hepatobiliary Complications of HCT
George McDonald, MD

9:00 AM **EN v. PN – Nutritional Supplementation Early After HCT – Enteral or Parenteral?**
Kerry K. McMillen, MS, RD, CSO, FAND

9:20 AM **Emerging Evidence on the Pathobiology and Biomarkers of Regimen-Related Mucosal Injury**
Pavan Reddy, MD

9:40 AM **Mechanisms of Gastrointestinal Injury in HCT – Learning from IBD**
Louis Cohen, MD

10:00 AM **Q&A with Speakers**

10:15 AM Break

Mechanisms of Toxicity

MODERATORS: Miguel-Angel Perales, MD and Shernan Holtan, MD

10:30 AM **Accelerated Functional Aging and Sarcopenia After HCT**
Jessica M. Scott, MD

10:50 AM **Association of the Pulmonary Virioma and Post-HCT Pulmonary Toxicities**
Caroline Lindemans, MD, PhD

11:10 AM **Strategies to Improve Immune Reconstitution After HCT and Novel Cellular Therapies**
Stefan Nierkens, PhD

11:30 AM **Association of Patient and Donor Clonal Hematopoiesis with HCT Toxicities**
Mareike Frick, MD

11:50 AM **Harmonizing Conditioning Regimens – How PK/PD Impacts Toxicities and Outcomes**
JJ Boelens, MD, PhD

12:10 PM **Q&A with Speakers**

Lunch Breakout Seminars

12:45 PM **Harnessing Biotech Innovations and Telemedicine Potential in HCT and Cellular Therapies**
ROOM 136

MODERATORS:
William A. Wood, MD
Michael Scordo, MD

SPEAKERS:
Chris Bredeson, MD, MSc, FRCPC
Christian Otto, MD, MMSc, DABFM

Using Dynamic Scoring Systems to Predict and Prevent NRM After HCT
ROOM 105

MODERATORS:
Miguel Perales, MD
Sergio A. Giral, MD

SPEAKERS:
Thomas Luft, MD, PhD
Andrea Bacigalupo, MD

SCHEDULE

Live Simulcast Available
Visit mskcc.org/toxicities for more information

Psychosocial, Quality of Life, and Caring for Unique Populations in HCT and Cellular Therapies

MODERATORS: Maria Cancio, MD and William A. Wood, MD

- 2:15 PM **Chronic Disease Burden in Survivors of Childhood HCT**
Melissa Hudson, MD
- 2:35 PM **Toxicities and Outcomes in the Geriatric Patient After HCT and Cellular Therapies**
Andrew Artz, MD, MS
- 2:55 PM **"It Takes a Village" – Impact of Psychosocial Risk on HCT Outcomes**
Karen Syrjala, PhD
- 3:15 PM **Patient-Reported Outcomes and Symptom Burden After CAR T Cell Therapy**
Navneet Majhail, MD, MS
- 3:35 PM **End-of-Life Care in HCT: What Do HCT Physicians Think About Palliative Care?**
Areej R. El-Jawahri, MD
- 3:55 PM **Q&A with Speakers**
- 4:10 PM Break

The Cost of HCT and Cellular Therapies – From Symptoms, to Pockets, and Beyond

MODERATORS: Minoo Battiwalla, MD, MS and Gabriela Rondon, MD

- 4:25 PM **Choosing Wisely in HCT and Its Applicability to Novel Cellular Therapies**
Sita Bhella, MEd, MD
- 4:45 PM **Are CAR T Cells and Novel Cellular Therapies Cost-effective?**
John K. Lin, MD
- 5:05 PM **The Short and Long-Term Costs of Critical Illness After HCT and Cellular Therapies**
Christine Duncan, MD
- 5:25 PM **Impact of Financial and Socioeconomic Burden on HCT Outcomes**
Kira Bona, MD, MPH
- 5:45 PM **Importance of Standardizing Cause-specific Death Adjudication After HCT and Cellular Therapies**
Theresa Hahn, PhD
- 6:05 PM **Q&A with Speakers**

Networking Reception & Poster Abstract Session

Course attendees are invited to join the faculty for a networking reception and poster abstract session immediately following the conclusion of day one from 6:15-7:30 PM at Zuckerman Research center. Hors d'oeuvres and refreshments will be served.

DAY 2 • SATURDAY, OCTOBER 12

7:30 AM Breakfast

Morning Seminar/Debate

MODERATORS: Hillard Lazarus, MD, FACP and Kenneth R. Cooke, MD

- 8:00 AM **Harmonizing VOD/SOS Diagnosis and Classification**
Mitchell Cairo, MD
Richard J. Jones, MD
George McDonald, MD

Keynote Address

- 8:50 AM  **Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy**
Bronwen E Shaw, MD, PhD

Investigational Research in Toxicities – From Bench to Bedside


MODERATORS: Navneet S. Majhail, MBBS, MD, MS and Michael Scordo, MD

- 9:35 AM **Use of Non-Genotoxic Conditioning to Mitigate Regimen-Related Toxicity**
Rajni Agarwal-Hashmi, MD
- 10:00 AM **The Injured Endothelium in HCT Toxicities**
Christopher Dandoy, MD, MS
- 10:25 AM **Virus specific T cells to Mitigate Infectious Complications After HCT**
Pawel Muranski, MD
- 10:45 AM Break
- 11:05 AM **Human Microbiome in Hematopoiesis and Immune Recovery After HCT and Cellular Therapies**
Ami Bhatt, MD, PhD
- 11:25 AM **Novel Biomarkers of Acute and Chronic Renal Injury After HCT and Cellular Therapies**
Benjamin Laskin, MD, MS
- 11:45 AM **Incorporating Biomarkers of Non-GVHD Toxicity in Clinical Trial Design**
Shernan Holtan, MD
- 12:05 PM **Q&A with Speakers**

Keynote Address

- 12:20 PM  **Preventing All-Cause Death after HCT – What Should be our Focus when Designing Trials?**
Andrea Bacigalupo, MD

1:00 PM Symposium Adjourn

Join the conversation: 
#MSKToxTCT | @MSKCME

mskcc.org/toxicities

REGISTRATION

REGISTRATION FEES	EARLY*	GENERAL
Physicians (MDs, PhDs, PharmDs and DOs)	\$350	\$400
Advanced Practice Providers, Nurses, Data Managers and Other Healthcare Providers	\$200	\$250
Residents, Fellows	\$150	\$200
Industry Professionals**	\$650	\$700
Live Simulcast	--	\$600

*Early registration rates available through August 31, 2019.

**Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

REGISTER ONLINE:

mskcc.org/toxicities

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- MSK CME offers a **discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners**. If you are a member of one of these groups, please contact cme@mskcc.org for more information.
- **MSK employee registration is complimentary**. However, you must complete course registration in order to attend this course.

Location & Accommodations

**Memorial Sloan Kettering Cancer Center
Zuckerman Research Center**
417 East 68th Street
New York, NY

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, visit: mskcc.org/cme

IN COLLABORATION WITH

UNC Lineberger Comprehensive Cancer Center
American Society for Transplantation and Cellular Therapy (ASTCT)
MD Anderson Cancer Center
Cleveland Clinic
Vanderbilt-Ingram Cancer Center
University of Minnesota
Sarah Cannon Center for Blood Cancer
Johns Hopkins Sidney Kimmel Cancer Center



Accreditation



Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

MSK designates this live activity for a maximum of **14.50 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.



**Memorial Sloan Kettering
Cancer Center**

w: mskcc.org/cme
e: cme@mskcc.org